论文部分内容阅读
宫颈癌是妇科常见的恶性肿瘤,其发生与人乳头瘤病毒(HPV),尤其是它的16、18型的感染密切相关。约90％的肿瘤细胞中可有HPVDNA,尤其是HPV16、18型基因外显子6、7(E_6、E_7)编码的两种蛋白的持续表达。这样肿瘤细胞中的E_6、E_7蛋白可作为肿瘤免疫治疗的特异性靶目标。已有若干证据表明E_6、E_7制备的HPV-抗原引导的免疫治疗对实验性和临床的宫颈癌有控制作用,其免疫治疗的主要机理就在于激发了特异性细胞毒性T淋巴细胞(CTL)的反应。本文作者以重组人乳头瘤病毒16、18型编码E_6、E_7蛋白序列(TA-HPV)的病毒疫苗修饰型为基础,首次在人体上进行了宫颈癌病毒疫苗免疫治疗的临床试验。初步结果表明用此病毒疫苗引起的HPV特异性的免疫反应既安全又有效。
Cervical cancer is a common malignant tumor in gynecology and its occurrence is closely related to the infection of human papillomavirus (HPV), especially its type 16 and type 18. Approximately 90% of the tumor cells may have sustained expression of HPVDNA, especially two proteins encoded by Exon 6,7 (E_6, E_7) of HPV16,18 gene. This tumor cells E_6, E_7 protein can be used as a specific target for tumor immunotherapy. There are a number of evidences that HPV-antigen-directed immunotherapy prepared by E_6 and E_7 has a control effect on experimental and clinical cervical cancer. The main mechanism of immunotherapy is the activation of specific cytotoxic T lymphocytes (CTLs) reaction. Based on the modified vaccine type of recombinant human papillomavirus type 16 and 18 E_6 and E_7 protein sequences (TA-HPV), the clinical trial of cervical cancer virus vaccine immunotherapy was first conducted on human body. Preliminary results indicate that the HPV-specific immune response elicited by this virus vaccine is both safe and effective.